PXMB.F Stock Overview

Develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. More details

PXMB.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 67.5% below our estimate of its fair value

Earnings are forecast to grow 57.23% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Does not have a meaningful market cap ($1B)

My Notes

Capture your thoughts, links and company narrative

Paxman AB (publ) Competitors

FONAR

NasdaqCM:FONR

US$97.1m

Sensus Healthcare

NasdaqCM:SRTS

US$114.1m

Pro-Dex

NasdaqCM:PDEX

US$169.5m

Kewaunee Scientific

NasdaqGM:KEQU

US$175.5m

Price History & Performance

Summary of share price highs, lows and changes for Paxman
Historical stock prices
Current Share Price	SEK 3.50
52 Week High	SEK 3.50
52 Week Low	SEK 2.80
Beta	0.84
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-42.81%
5 Year Change	n/a
Change since IPO	-47.68%

Recent updates

Shareholder Returns

	PXMB.F	US Medical Equipment	US Market
7D	0%	1.6%	0.7%
1Y	n/a	9.2%	23.9%

Return vs Industry: Insufficient data to determine how PXMB.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how PXMB.F performed against the US Market.

Price Volatility

Is PXMB.F's price volatile compared to industry and market?
PXMB.F volatility
PXMB.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PXMB.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PXMB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	94	Richard Paxman	paxmanscalpcooling.com

Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device.

Paxman AB (publ) Fundamentals Summary

How do Paxman's earnings and revenue compare to its market cap?
PXMB.F fundamental statistics
Market cap	US$97.12m
Earnings (TTM)	US$2.28m
Revenue (TTM)	US$22.37m

42.7x

P/E Ratio

4.3x

P/S Ratio

Is PXMB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PXMB.F income statement (TTM)
Revenue	SEK 235.60m
Cost of Revenue	SEK 78.32m
Gross Profit	SEK 157.29m
Other Expenses	SEK 133.32m
Earnings	SEK 23.97m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 21, 2024

Earnings per share (EPS)	1.26
Gross Margin	66.76%
Net Profit Margin	10.17%
Debt/Equity Ratio	12.6%

How did PXMB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/13 00:59
End of Day Share Price	2024/05/16 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paxman AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mats Hyttinge	Redeye

Paxman OTCPK:PXMB.F Stock Report